Terminated PHASE3 INTERVENTIONAL 2-arm NCT05181540

A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation (E-CELERATE)

A Phase 3 Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of AB-205 Plus Standard of Care Versus Placebo Plus Standard of Care in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT) (E-CELERATE)

Sponsor: Angiocrine Bioscience

Conditions Hodgkin Lymphoma Non Hodgkin Lymphoma

Interventions AB-205 Placebo

Updated 21 times since 2022 Last updated: Jan 31, 2025 Started: Feb 21, 2022 Primary completion: Dec 29, 2023 Completion: Jan 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Interim analysis showed lack of efficacy

This PHASE3 trial investigates Hodgkin Lymphoma and Non Hodgkin Lymphoma and is currently terminated or withdrawn. Angiocrine Bioscience leads this study, which shows 21 recorded versions since 2022 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

21 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Mar 2025 — Sep 2025 [monthly]

Terminated PHASE3
Sep 2024 — Mar 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Feb 2024 — Jul 2024 [monthly]

Terminated PHASE3

Status: Recruiting → Terminated

▶ Show 16 earlier versions

Dec 2023 — Feb 2024 [monthly]

Recruiting PHASE3
Nov 2023 — Dec 2023 [monthly]

Recruiting PHASE3
Sep 2023 — Nov 2023 [monthly]

Recruiting PHASE3
Jul 2023 — Sep 2023 [monthly]

Recruiting PHASE3
Jun 2023 — Jul 2023 [monthly]

Recruiting PHASE3
Mar 2023 — Jun 2023 [monthly]

Recruiting PHASE3
Feb 2023 — Mar 2023 [monthly]

Recruiting PHASE3
Jan 2023 — Feb 2023 [monthly]

Recruiting PHASE3
Dec 2022 — Jan 2023 [monthly]

Recruiting PHASE3
Nov 2022 — Dec 2022 [monthly]

Recruiting PHASE3
Sep 2022 — Nov 2022 [monthly]

Recruiting PHASE3
Jul 2022 — Sep 2022 [monthly]

Recruiting PHASE3
Jun 2022 — Jul 2022 [monthly]

Recruiting PHASE3
May 2022 — Jun 2022 [monthly]

Recruiting PHASE3
Apr 2022 — May 2022 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Feb 2022 — Apr 2022 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Angiocrine Bioscience
California Institute for Regenerative Medicine (CIRM)

Data source: Angiocrine Bioscience

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Atlanta, United States , Baltimore, United States , Boston, United States , Chicago, United States , Columbus, United States , Denver, United States , Duarte, United States , Gilbert, United States , Hackensack, United States and 15 more locations